A Riva
Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer
Pagani O, Riva A, Graffeo R, Zimatore M, Zampino G, Bauer J, Borner M, Hess D, Thürlimann B, Buonadonna A, Crivellari D, Martinelli G, Sessa C, Goldhirsch A. Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999; 10:539-45.
May 1, 1999Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer
May 1, 1999Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999; 10:539-45
Pagani O, Riva A, Graffeo R, Zimatore M, Zampino G, Bauer J, Borner M, Hess Dagmar, Thürlimann Beat, Buonadonna A, Crivellari D, Martinelli G, Sessa C, Goldhirsch A
Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer
Nabholtz J, Murawsky M, Alaki M, Aapro M, Drbal J, Trillet-Lenoir V, Rosso R, Rapoport B, Vandenberg T, Douma J, Deschênes L, Melnychuk D, Bezwoda W, Thürlimann B, Riva A. Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer. Oncology (Williston Park, N.Y.) 1997; 11:25-30.
Aug 1, 1997Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer
Aug 1, 1997Oncology (Williston Park, N.Y.) 1997; 11:25-30
Nabholtz J M, Murawsky M, Alaki M, Aapro M S, Drbal J, Trillet-Lenoir V, Rosso R, Rapoport B, Vandenberg T A, Douma J, Deschênes L, Melnychuk D, Bezwoda W R, Thürlimann Beat, Riva A